NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01179217,A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia,https://clinicaltrials.gov/study/NCT01179217,,COMPLETED,The purpose of this research is to evaluate the effects of L-glutamine as a therapy for Sickle Cell Anemia or Sickle ß0 Thalassemia as evaluated by the number of occurrences of sickle cell crises.,YES,Sickle Cell Anemia|Sickle ß0-Thalassemia,DRUG: L-glutamine|DRUG: Placebo,"The Number of Occurrences of Sickle Cell Crises, The number of occurrences of protocol-defined sickle cell crises that occur from Week 0 to Week 48 will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia., 48 weeks","The Number of Hospitalizations for Sickle Cell Pain, The number of hospitalizations that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia., 48 weeks|The Number of Emergency Room/Medical Facility Visits for Sickle Cell Pain, The number of emergency room visits or medical facility visits that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia., 48 weeks|The Effect of Oral -L-glutamine on Hematological Parameters, To assess the effect of oral L-glutamine on hematological parameters (hemoglobin), Change from Baseline will be reported at Weeks 4, 24 and 48., Baseline, Week 4, 24 and 48|The Effect of Oral L-glutamine on Vital Signs, To assess the effect of oral L-glutamine on Vital signs (systolic and diastolic blood pressure). Change from Baseline will be reported at Weeks 4, 24, and 48., Baseline, Week 4, 24, and 48|The Effect of Oral L-glutamine on Hematological Parameters, To assess the effect of oral L-glutamine on hematological parameters (hematocrit), Change from Baseline will be reported at Weeks 4, 24 and 48., Baseline, Week 4, 24 and 48|The Effect of Oral L-glutamine on Hematological Parameters, To assess the effect of oral L-glutamine on hematological parameters (reticulocyte count), Change from Baseline will be reported at Weeks 4, 24 and 48., Baseline, Week 4, 24 and 48|The Effect of Oral L-glutamine on Vital Signs, To assess the effect of oral L-glutamine on Vital signs (pulse rate). Change from Baseline will be reported at Weeks 4, 24, and 48., Baseline, Week 4, Week 24 and Week 48|Effect of Oral L-glutamine on Vital Signs, To assess the effect of oral L-glutamine on Vital signs (temperature). Change from Baseline will be reported at Weeks 4, 24, and 48., Baseline, Week 4, Week 24 and Week 48|The Effect of Oral L-glutamine on Vital Signs, To assess the effect of oral L-glutamine on Vital signs (respiration). Change from Baseline will be reported at Weeks 4, 24, and 48., Baseline, Week 4, Week 24 and Week 48",,"Emmaus Medical, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",GLUSCC09-01,2010-05,2014-03,2014-03,2010-08-11,2017-08-10,2020-08-19,"University of South Alabama Medical Center, Mobile, Alabama, 36617, United States|Phoenix Children's Hospital Center for Cancer and Blood Disorders, Phoenix, Arizona, 85016, United States|Kaiser Permanente, Inglewood, California, 90301, United States|Children's Hospital & Research Center at Oakland, Oakland, California, 94609, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|Harbor-UCLA Medical Center, Torrance, California, 90509, United States|University of Denver School of Medicine Sickle Cell Treatment & Research Center, Aurora, Colorado, 80045, United States|Howard University Hospital & Howard University, Washington, District of Columbia, 20060, United States|University of Florida, Gainesville, Florida, 32610-0296, United States|All Children's Hospital, Saint Petersburg, Florida, 33701, United States|Children's Healthcare of Atlanta at Egleston/Emory University, Atlanta, Georgia, 30322, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Louisville School of Medicine, Louisville, Kentucky, 40202, United States|Sickle Cell Center of S. Louisiana, Tulane University School of Medicine, New Orleans, Louisiana, 70112, United States|Johns Hopkins University, Baltimore, Maryland, 21205, United States|Boston University Medical Center, Boston, Massachusetts, 02118, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States|Children's Specialty Center of Nevada, Las Vegas, Nevada, 89109, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, 89109, United States|Cooper University Hospital, Camden, New Jersey, 08103, United States|Bronx Lebanon Hospital, Bronx, New York, 11203, United States|The Brooklyn Hospital Center, Brooklyn, New York, 11201, United States|SUNY - Downstate Medical Center, Brooklyn, New York, 11203, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, 11212, United States|New York Methodist Hospital - SC/Thalassemia Program, Brooklyn, New York, 11215, United States|Interfaith Medical Center, Brooklyn, New York, 11238, United States|Presbyterian Blume Pediatric Hematology-Oncology Clinic, Charlotte, North Carolina, 28204, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, 38104, United States|Virginia Commonwealth University, Richmond, Virginia, 23298-0306, United States",
